TP53 and myelodysplastic syndrome: Previous studies in MDS [11, 25] have already demonstrated that monoallelic lesions have no clinical impact on prognosis vs. TP53WT cases, but biallelic clones defined by the presence of two TP53 lesions have more aggressive phenotypes.